{
    "clinical_study": {
        "@rank": "19951", 
        "arm_group": [
            {
                "arm_group_label": "TisssueGene-C (Low dose)", 
                "arm_group_type": "Experimental", 
                "description": "TisssueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue"
            }, 
            {
                "arm_group_label": "Experimental: TisssueGene-C (High dose)", 
                "arm_group_type": "Experimental", 
                "description": "TisssueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether TissueGene-C, allogeneic human\n      chondrocytes expressing TGF-b1, mixed with fibrin-glue is effective and safe  in patients\n      with degenerative arthritis."
        }, 
        "brief_title": "Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Degenerative Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Osteoarthritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "TissueGene-C is a biological new drug which consists of non-transduced chondrocytes and\n      transduced chondrocytes that express TGF-b1 to regenerate the damaged cartilage.\n\n      During the clinical trial Phase 2, the investigators compare  low dose or high dose\n      TissueGene-C in 12 - months trial with 18 outpatients who have degenerative arthritis.  The\n      patients are randomized to two dose levels of TissueGene-C by 1:1 ratio, and they are\n      monitored and recorded for  alleviating symptoms, sports activities, function of the knee,\n      and the presence of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients at least 18 years of age\n\n          -  Patients with IKDC score of 60 or below\n\n          -  Body Mass Index (BMI) between '18.5 - 30.0.'\n\n          -  Clinical diagnosis of degenerative arthritis\n\n          -  ICRS of grade IV, defect 2 cm2 ~ 10cm2\n\n          -  Female patients of childbearing potential must agree to practice adequate methods of\n             birth control to prevent pregnancy during the study\n\n          -  Patients who voluntarily agreed to enroll in the study and signed an informed consent\n             form\n\n        Exclusion Criteria:\n\n          -  Mechanical axis (HKA) is greater than 5\u00b0\n\n          -  Patients with abnormal hematology, serum chemistry, or urinalysis screening\n             laboratory results\n\n          -  Patients taking steroidal anti-inflammatory medications within 14 days of baseline\n             visit unless washed out\n\n          -  Patients receiving injections to the treated knee within 2 months prior to study\n             entry\n\n          -  Patients with ongoing infectious disease, including HIV\n\n          -  Patients with clinically significant cardiovascular, renal, hepatic, endocrine\n             disease, cancer, Type I diabetes\n\n          -  Patients who are pregnant or currently breast-feeding children\n\n          -  Patients who were enrolled in any other clinical trials within the past 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825811", 
            "org_study_id": "KS-TGC(S)-01-2"
        }, 
        "intervention": [
            {
                "arm_group_label": "TisssueGene-C (Low dose)", 
                "description": "Tissuege-C at 1.0 x 10^6 cells mixed with fibrin-glue", 
                "intervention_name": "TisssueGene-C (Low dose)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Experimental: TisssueGene-C (High dose)", 
                "description": "Tissuege-C at 3.0 x 10^6 cells mixed with fibrin-glue", 
                "intervention_name": "TisssueGene-C (High dose)", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cell mediated gene therapy", 
            "Osteoarthritis", 
            "Fibrin-glue", 
            "Degenerative Arthritis"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "700-721"
                    }, 
                    "name": "Kyungpook National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "400-711"
                    }, 
                    "name": "Inha University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158-710"
                    }, 
                    "name": "Ewha Womans University Mokdong Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-blind, Randomized, Parallel-group, Multi-center Phase 2 Study to Determine the Efficacy and Safety of TissueGene-C Mixed With Fibrin-glue in Patients With Degenerative Arthritis", 
        "overall_official": [
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Myung Chul Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Chul Won Ha, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Seong Il Bin, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inha University Hospital", 
                "last_name": "Myung Gu Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ewha Womans University Mokdong Hospital", 
                "last_name": "Jae Doo Yoo, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyungpook National University", 
                "last_name": "Hee Su Kyung, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)", 
            "measure": "Changes in IKDC Subjective Knee Evaluation", 
            "safety_issue": "No", 
            "time_frame": "Week 0, 24 and 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825811"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC)", 
                "measure": "Changes in WOMAC scores", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 24 and 48"
            }, 
            {
                "description": "Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS)", 
                "measure": "Changes in KOOS scores", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 24 and 48"
            }, 
            {
                "description": "Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)", 
                "measure": "Changes in 100 mm-VAS", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 24 and 48"
            }, 
            {
                "description": "Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 following dosing by an independent radiographic reviewer", 
                "measure": "Comparative Evaluation of Knee Magnetic Resonance Images (MRIs)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 24 and 48"
            }, 
            {
                "measure": "Changes in ICRS Cartilage Repair Assessment", 
                "safety_issue": "No", 
                "time_frame": "week 0 and 48"
            }
        ], 
        "source": "Kolon Life Science", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kolon Life Science", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}